Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average PT from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been given a consensus rating of “Moderate Buy” by the eight research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $55.50.

Several research analysts have weighed in on TVRD shares. Raymond James Financial downgraded Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Piper Sandler lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday, October 13th. Finally, BTIG Research cut their price objective on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, October 13th.

Tvardi Therapeutics Trading Up 4.8%

NASDAQ:TVRD opened at $3.72 on Thursday. The firm has a market cap of $34.89 million, a price-to-earnings ratio of -0.39 and a beta of 0.14. The company’s 50-day moving average is $4.20 and its two-hundred day moving average is $15.30. Tvardi Therapeutics has a 12-month low of $3.50 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

Several institutional investors have recently made changes to their positions in TVRD. Slate Path Capital LP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $16,427,000. 683 Capital Management LLC acquired a new stake in Tvardi Therapeutics during the second quarter worth about $4,107,000. Vestal Point Capital LP purchased a new position in shares of Tvardi Therapeutics in the 3rd quarter worth about $6,508,000. Geode Capital Management LLC purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter worth about $2,617,000. Finally, Invesco Ltd. acquired a new position in shares of Tvardi Therapeutics in the 3rd quarter valued at about $3,219,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.